Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
Startek honored with the AAA DI-verse Certification for disability inclusion excellence
Recognition marks Startek's commitment to building an inclusive and accessible workplace for all…
